Clinical Trial Detail

NCT ID NCT01004224
Title A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

transitional cell carcinoma

Advanced Solid Tumor

Therapies

Infigratinib

Age Groups: adult

Additional content available in CKB BOOST